FINWIRES · TerminalLIVE
FINWIRES

モルガン・スタンレーは、シェフズ・ウェアハウスの第1四半期決算は力強い成長を背景に「高級品市場の明るい兆し」と評価した。

By

-- モルガン・スタンレーは木曜日のレポートで、シェフズ・ウェアハウス（CHEF）が第1四半期に好調な業績を上げたと発表した。主要指標は軒並み予想を上回り、中核事業の勢いをさらに強固なものにした。オーガニック売上高成長率は10.4%に達し、市場予想の約7%を大きく上回った。 アナリストらは、好調な業績は販売量の力強い伸びと好調な商品構成に支えられ、4.1%のインフレ率も貢献したと指摘。調整後EBITDA（金利・税金・減価償却費控除前利益）は6,000万ドルと予想を上回り、営業効率と売上高の好調により利益率は約70ベーシスポイント上昇し5.7%となった。 モルガン・スタンレーは、中東情勢への懸念は当初の予想ほど深刻ではなく、第1四半期の売上高はわずか約50ベーシスポイントのマイナス要因にとどまったと述べた。販売量は前年同期比約75%で推移しており、状況が続けば月間約50ベーシスポイントのマイナス要因となる可能性がある。 調査担当者らは、今四半期も勢いが継続しており、4月も2桁のオーガニック成長率を維持していることから、マクロ経済環境がまちまちであるにもかかわらず、需要が堅調であることを指摘した。 モルガン・スタンレーは同社株の投資判断を「オーバーウェイト」に据え置き、目標株価を76ドルから83ドルに引き上げた。

Price: $76.14, Change: $+0.36, Percent Change: +0.48%

Related Articles

Treasury

TD Bank Group Issues 150 Million Swiss francs Green Bond

Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.

$TD$TD.TO
Research

Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.

$AMGN
Research

Research Alert: Illumina: Sequencing Sales Growth Supports Q1 Eps Beat, Guidance Increased

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Illumina reported Q1 2026 adjusted EPS of $1.15, up 18.6% Y/Y and beating the $1.05 consensus estimate, while revenue grew 4.8% to $1.091B. Operating leverage was evident, with adjusted operating margin expanding 150 bps Y/Y to 21.9% due to consumables growth of 4.3% to $726M and instruments up 8.3% to $118M. The instrument growth suggests continued NovaSeq X adoption momentum, while rest-of-world organic revenue growth of 3.5% indicates healthy demand outside of China (declined 29% organically). ILMN raised full-year guidance, increasing revenue expectations by $20M at the midpoint to $4.52B-4.62B and adjusted EPS to $5.15-5.30 from $5.05-5.20. We view the recently-completed SomaLogic acquisition positively, as it expands ILMN's addressable market into proteomics and strengthens its multiomics portfolio. Strong cash generation was also present, with operating cash flow up 20.4% to $289M, supporting the newly-authorized $1.5B share repurchase program.

$ILMN